spironolactone has been researched along with Atrophy in 7 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Corticosterone or vehicle was injected twice daily in rats from 8 to 12 weeks of age." | 1.39 | Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. ( Hattori, T; Iwase, E; Miyachi, M; Murase, T; Murohara, T; Nagata, K; Ohtake, M; Takahashi, K; Tsuboi, K, 2013) |
| "Eplerenone (Inspra) is an aldosterone receptor antagonist approved for the treatment of hypertension and heart failure after a myocardial infarction." | 1.39 | Prostate effect in dogs with the aldosterone receptor blocker eplerenone. ( Bell, RR; John-Baptiste, A; Levin, S; McMahon, E, 2013) |
| "The incidence of primary aldosteronism in patients with difficult to treat hypertension is higher than previously stated in texts." | 1.32 | [Treatment refractory hypertension with atrophic kidney: attending to one and not neglecting the other]. ( Guertler, M; Suter, PM; Vetter, W, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 1 |
| Yu, Y | 1 |
| Qiao, J | 1 |
| Zhu, L | 1 |
| Xiao, Z | 1 |
| Hattori, T | 1 |
| Murase, T | 1 |
| Iwase, E | 1 |
| Takahashi, K | 1 |
| Ohtake, M | 2 |
| Tsuboi, K | 1 |
| Miyachi, M | 1 |
| Murohara, T | 1 |
| Nagata, K | 1 |
| Maubec, E | 1 |
| Laouénan, C | 1 |
| Deschamps, L | 1 |
| Nguyen, VT | 1 |
| Scheer-Senyarich, I | 1 |
| Wackenheim-Jacobs, AC | 1 |
| Steff, M | 1 |
| Duhamel, S | 1 |
| Tubiana, S | 1 |
| Brahimi, N | 1 |
| Leclerc-Mercier, S | 1 |
| Crickx, B | 1 |
| Perret, C | 1 |
| Aractingi, S | 1 |
| Escoubet, B | 1 |
| Duval, X | 1 |
| Arnaud, P | 1 |
| Jaisser, F | 1 |
| Mentré, F | 1 |
| Farman, N | 1 |
| Levin, S | 1 |
| McMahon, E | 1 |
| John-Baptiste, A | 1 |
| Bell, RR | 1 |
| Guertler, M | 1 |
| Vetter, W | 1 |
| Suter, PM | 1 |
| Smith, SH | 1 |
| Bishop, SP | 1 |
| Basinger, GT | 1 |
| Gittes, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy[NCT01407471] | Phase 2 | 26 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for spironolactone and Atrophy
| Article | Year |
|---|---|
Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.
Topics: Administration, Topical; Adult; Atrophy; Biopsy, Needle; Clobetasol; Dermoscopy; Double-Blind Method | 2015 |
6 other studies available for spironolactone and Atrophy
| Article | Year |
|---|---|
Mineralocorticoid receptor excessive activation involved in glucocorticoid-related brain injury.
Topics: Animals; Apoptosis; Atrophy; Blood Pressure; Brain Injuries; Dexamethasone; Fibrosis; Glucocorticoid | 2020 |
Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism.
Topics: Animals; Atrophy; Blood Pressure; Corticosterone; Disease Models, Animal; Fibrosis; Heart Diseases; | 2013 |
Prostate effect in dogs with the aldosterone receptor blocker eplerenone.
Topics: Animals; Atrophy; Dihydrotestosterone; Dogs; Eplerenone; Finasteride; Histocytochemistry; Male; Mine | 2013 |
[Treatment refractory hypertension with atrophic kidney: attending to one and not neglecting the other].
Topics: Adult; Antihypertensive Agents; Atrophy; Diagnosis, Differential; Drug Resistance; Drug Therapy, Com | 2003 |
Selection criteria for drug-treated animals in two-kidney, one clip renal hypertension.
Topics: Animals; Atrophy; Constriction; Hydralazine; Hypertension, Renal; Kidney; Male; Organ Size; Rats; Ra | 1986 |
Antiandrogenic effect of spironolactone in rats.
Topics: Androgen Antagonists; Animals; Atrophy; Body Weight; Cytoplasm; Epithelial Cells; Injections, Subcut | 1974 |